Disclaimer: MercyIowaCityClinics.org is an independent editorial publication and is not affiliated with any hospital, clinic, or medical provider. GLP-3R is a research peptide — not approved for human consumption. These statements have not been evaluated by the FDA.
Swole AF Labs' GLP-3R: A Triple-Agonist Research Peptide Built on Lilly's Retatrutide Blueprint
Swole AF Labs markets GLP-3R as a synthetic 39-amino-acid research peptide designed to target three distinct receptor pathways—GLP-1R, GIPR, and GCGR—making it a triple-agonist compound. The peptide's design mirrors Eli Lilly's retatrutide (LY3437943), currently advancing through Phase 3 clinical trials with reported body weight reduction data hovering around 28–30% over 68–80 weeks. For context, this positions GLP-3R mechanistically above both semaglutide (single-receptor GLP-1R agonist, ~15% weight loss) and tirzepatide (dual-receptor GLP-1R/GIPR agonist, ~22% weight loss) in terms of receptor engagement breadth. However, the MICC Review Team finds significant transparency gaps and credibility concerns specific to Swole AF Labs' product, sourcing claims, and vendor history that warrant careful examination before any research consideration.
No Finnrick-Verified Testing: The Transparency Gap That Matters
The most critical issue facing Swole AF Labs' GLP-3R product is the absence of independently verified third-party testing through Finnrick Analytics, an industry-standard purity verification platform that tracks authenticated retatrutide samples from legitimate vendors. Unlike competitors offering Finnrick-verified retatrutide certificates, Swole AF Labs' claimed third-party testing lacks this independent corroboration. While the vendor asserts that GLP-3R undergoes third-party analysis, the MICC Review Team found no publicly accessible, independently verified certificates confirming peptide purity, amino-acid sequence accuracy, or contaminant absence. This represents a significant red flag for researchers evaluating compound authenticity. In a research market plagued by counterfeit peptides and mislabeled products, Finnrick verification—or equivalent independent third-party validation—functions as a baseline credibility marker. Swole AF Labs' absence from Finnrick's verified vendor database suggests either limited testing documentation or deliberate non-participation in transparent verification systems. Either scenario raises questions about confidence in product identity and consistency.
The Rebrand from Swole AF Labs to SAF Research: Distancing Strategy or Business Evolution?
Swole AF Labs has undergone a corporate rebrand, transitioning from its original “Swole AF Labs” identity to “SAF Research” and “SAF Peptides” under the domain saf-research.com (formerly swolepeptides.com). While rebranding occurs for legitimate business reasons, the timing and messaging of this transition merit scrutiny. The MICC Review Team observed that the rebrand coincides with the vendor's expansion into higher-priced research compounds like GLP-3R—a shift that could reflect genuine business maturation or calculated distancing from the original brand's reputation. Industry reviewers have historically raised questions about Swole AF Labs' lab testing credibility and product consistency. The rebrand may indicate acknowledgment of those concerns and a reset attempt, or it may represent a marketing tactic to obscure earlier negative associations. Without explicit public statements addressing previous credibility questions, the rebrand carries ambiguity that prospective researchers should factor into vendor trust assessments.
Pricing Strategy and Perpetual BOGO Promotions: Cost Obfuscation Concerns
Swole AF Labs' GLP-3R pricing structure runs noticeably higher than competitors offering similarly dosed or Finnrick-verified retatrutide products. More concerning, the vendor employs perpetual “buy-one-get-one” promotional offers that obscure true cost-per-milligram calculations. Perpetual BOGO deals—promotions that remain “always active”—suggest either inflated baseline pricing or deliberate cost obfuscation to mask competitive disadvantages. When a vendor's primary promotional mechanism is perpetual rather than time-limited, researchers cannot determine what constitutes the vendor's actual, sustainable price point. This tactic may benefit cash flow and customer perception, but it undermines transparent cost comparison. Researchers evaluating multiple GLP-3R sources should calculate true cost-per-dose accounting for the BOGO structure rather than accepting advertised totals at face value. Higher pricing combined with unverified testing creates a cost-value mismatch compared to vendors offering Finnrick verification and transparent, non-promotional pricing.
Customer Reviews and Competitive Standing: Mixed Performance Against Tier-1 Vendors
Swole AF Labs' sarms.io rating of 7/10 places it in the “decent source with improvement over time” category—a middling position reflecting mixed customer experiences. The MICC Review Team's analysis of available customer feedback identified more negative reviews than those appearing for higher-rated competitors, with complaints spanning inconsistent peptide potency, customer service delays, and documentation gaps. While the 7/10 rating indicates the vendor has improved operationally, it simultaneously suggests unresolved performance gaps. Top-tier research peptide vendors consistently achieve 8.5–9.5 ratings with predominantly positive feedback, faster shipping, and documented third-party verification. Swole AF Labs' rating trajectory shows improvement but positions the vendor in a secondary tier where researchers accept greater risk and less independent verification in exchange for product availability. This positioning becomes particularly problematic for a high-value compound like GLP-3R, where purity and dosage accuracy carry significant research implications.
Clinical Data Foundation: Retatrutide Efficacy Versus SAF Labs' Unproven Formulation
The 28–30% body weight reduction data cited for GLP-3R derives entirely from Eli Lilly's TRIUMPH Phase 3 trial data for authentic retatrutide (LY3437943). Swole AF Labs makes no claims of conducting independent efficacy studies, toxicity assessments, or pharmacokinetic research on their GLP-3R formulation. This distinction is critical: Eli Lilly's data validates the triple-agonist mechanism in pharmaceutical-grade retatrutide under controlled conditions. Swole AF Labs' GLP-3R is a research-only chemical offering marketed on the basis of another company's clinical evidence, without independent verification that SAF's formulation achieves equivalent potency, purity, or bioavailability. Researchers considering this peptide should recognize that any assumed efficacy is extrapolated from Lilly's data and carries no validation specific to Swole AF Labs' production batch. The absence of independent pharmacological testing compounds this risk. Eli Lilly's FDA approval of retatrutide is anticipated around 2027, which may render research-grade retatrutide sources less relevant as the pharmaceutical becomes accessible through legitimate channels.
Risk Profile and Vendor Assessment: Transparency Gaps Demand Caution
Swole AF Labs' GLP-3R presents researchers with a risk-reward imbalance tilted toward increased uncertainty. The peptide's triple-agonist mechanism is mechanistically sound and based on Eli Lilly's validated research—a genuine advantage over single or dual-agonist alternatives. However, Swole AF Labs has failed to provide Finnrick-verified independent testing, carries historical credibility questions, employs opaque BOGO pricing, and maintains mixed customer reviews relative to tier-1 competitors. The company's rebrand from Swole AF Labs to SAF Research may indicate genuine operational improvement or strategic distancing—the ambiguity itself represents a trust deficit. For researchers prioritizing confidence in compound identity and purity, vendors offering Finnrick verification and transparent pricing present materially lower risk. The MICC Review Team acknowledges that Swole AF Labs has improved operationally and that their GLP-3R formulation may be legitimate; however, the absence of independent verification and the vendor's historical credibility concerns argue for alternative sources if available. If researchers select Swole AF Labs' GLP-3R, they must accept reduced transparency compared to verified competitors and conduct additional due diligence before committing to research protocols.
Compare Other GLP-3R Triple-Agonist Vendors
This review is part of our ongoing evaluation of research-grade retatrutide (GLP-3R) vendors. For a complete picture, see how other suppliers compare:
- The Sourced Peptides Retatrutide Review — ≥99% HPLC purity with batch-specific COA — among the more transparent vendors in this space
- Amino Asylum testing review — Finnrick-rated 78% (#2 of 223 vendors) with mixed dosage results but consistent purity
- Peptide Sciences testing analysis — 41 independent tests on record but only 51% pass rate — the most-tested vendor with inconsistent results
- The Nationwide Peptides Retatrutide Review — Claims ≥99% purity with COA (HPLC/MS) and GMP synthesis — not yet Finnrick-verified
Each vendor review examines purity testing, dosage accuracy, pricing, and transparency — the factors that matter most for research-grade peptide procurement.
These statements have not been evaluated by the FDA. GLP-3R is a research peptide not intended for human consumption. Always consult a qualified healthcare provider before considering any research compounds.